Casper joins EU-Startups podcast not only to talk about the benefits, but also the real challenges of startups building their tech stacks on black-box AI infrastructure, and the issue of uncertainty over upcoming regulations from the EU and other regulatory bodies.
Christian Lund, co-founder of Templafy, joins the board of directors at Abzu, the Danish-Spanish startup that builds and applies trustworthy AI to tackle complex challenges for the world’s leading companies.
Abzu, the Danish-Spanish startup that builds and applies trustworthy AI to tackle complex challenges for the world’s leading companies, secures ISO 27001:2022 certification, reinforcing its value proposition for explainable, resilient, and safe AI solutions.
Abzu, the Danish / Spanish startup that has introduced new methods and technology to drive discoveries and reduce R&D costs for pharmaceutical and biotech companies, is thrilled to win Best HealthTech at the 2023 Nordic Startup Awards.
Abzu® announced that the United States Patent and Trademark Office (USPTO) has issued Abzu Aps a patent number US 11,537,686 titled “Method of Deriving a Correlation” that protects the technology behind the pioneering QLattice algorithm.
Launched in collaboration with the Ethical AI Governance Group (EAIGG) and the Ethical AI Database (EAIDB), the Nordic Ethical AI Landscape is the only publicly available, vetted database of AI companies in the Nordics that provide ethical services.
To address the deficiency of treatments for rare diseases, the selected partners in project Elegant North will create a cross-border, rare disease data-sharing platform to foster cross-sector collaboration between researchers, companies, and healthcare systems.
Peptomyc used the QLattice and Abzu’s expertise in patient stratification to reveal early predictive response-biomarkers to treatment with OMO-103 in metastatic patients. The analysis by the QLattice was conducted on a very small clinical trial of 22 patients.
Abzu will be applying the €2.5 million grant to the development of the Abzu AI platform, a user-friendly and easy-to-operate platform built on the QLattice engine that makes interpretable and explainable predictions widely accessible.
Mette Kirstine Agger will help Abzu strengthen its position in life science and biotech by building a bridge between research and business development with her special experience in how new technologies can create and support growth and business opportunities within biotech and a wide range of other lines of industries.
Basel Area Business & Innovation, a non-profit agency dedicated to helping startups, institutions, and companies find business success in the Basel Area, was integral in supporting Abzu’s settlement and facilitating access to the thriving ecosystem.
Prior to the record-breaking seed round in Denmark of € 5.8 M, Abzu raised a total of € 2.9 M. Abzu plans to accelerate commercialization within pharmaceutical drug discovery and mature its AI platform for application in other industry verticals.
“My skepticism towards machine learning is that people apply very complicated models with lots of features to problems that are probably easier to solve. What I like about your product is that it takes into consideration that simpler models could also be a solution,” commented a user.